Statins and neuroprotection A prescription to move the field forward
Statins and neuroprotection A prescription to move the field forward
复制标题
DOI：
10.1111/j.1749-6632.2009.05359.x
复制
发表时间：
2010-01-01
期刊：
影响因子：
--
通讯作者：
Mueller, Walter E.
中科院分区：
文献类型：
--
作者：
Wood, W. Gibson;Eckert, Gunter P.;Mueller, Walter E.
人们越来越关注使用他汀类药物（HMG-CoA 还原酶抑制剂）来治疗特定的神经退行性疾病（例如脑血管疾病、帕金森病、阿尔茨海默病、多发性硬化症）和可能的创伤性脑损伤。关于他汀类药物治疗上述疾病的功效尚未达成共识，而且其所谓的他汀类药物诱导的神经保护机制也尚未得到充分了解。他汀类药物诱导的神经保护的部分支持来自使用动物模型和细胞培养的研究。这项工作产生了重要信息，但在与他汀类药物和大脑有关的基本问题上仍然缺乏进展，这阻碍了对他汀类药物如何改变大脑功能的理解的进展。例如，关于亲脂性和亲水性他汀类药物在大脑中的药代动力学、他汀类药物诱导的神经保护与细胞死亡以及他汀类药物和脑类异戊二烯的数据很少。本次小型审查的目的是检查上述问题并确定未来研究的方向。
There is growing interest in the use of statins, HMG-CoA reductase inhibitors, for treating specific neurodegenerative diseases (e.g., cerebrovascular disease, Parkinson's disease, Alzheimer's disease, multiple sclerosis) and possibly traumatic brain injury. Neither is there a consensus on the efficacy of statins in treating the aforementioned diseases nor are the mechanisms of the purported statin-induced neuroprotection well-understood. Part of the support for statin-induced neuroprotection comes from studies using animal models and cell culture. Important information has resulted from that work but there continues to be a lack of progress on basic issues pertaining to statins and brain that impedes advancement in understanding how statins alter brain function. For example, there are scant data on the pharmacokinetics of lipophilic and hydrophilic statins in brain, statin-induced neuroprotection versus cell death, and statins and brain isoprenoids. The purpose of this mini-review will be to examine those aforementioned issues and to identify directions of future research.